Industry News

Humanigen Announces COVID-19 Case Report Demonstrating Rapid Resolution and Discharge after Single IND Emergency Use Authorization of Lenzilumab™

10/06/2020

Excerpt from the Press Release: BURLINGAME, Calif.–(BUSINESS WIRE)–Humanigen, Inc., (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ today announced that a patient case report on the use of lenzilumab™ in critical COVID-19 was published online at OSF Preprints. The case report, titled “COVID-19 associated…

Read More

Innovation Pharmaceuticals Announces Pre-IND Meeting Request Granted by FDA for the Study of Brilacidin for the Treatment of COVID-19

10/05/2020

Excerpt from the Press Release: WAKEFIELD, MA – October 2, 2020 (GLOBE NEWSWIRE) Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced that earlier this week the Company submitted a pre-IND meeting request to the FDA in advance of a planned study of Brilacidin, a defensin-mimetic drug candidate, for the treatment of…

Read More

Javelin Biotech Aims to Develop Industry-Leading “Organ-on-a-Chip” Predictive Pharmacokinetics Platform in Collaboration with Pfizer Inc.

10/02/2020

Excerpt from the Press Release: WOBURN, Mass.–(BUSINESS WIRE)–Javelin Biotech (“Javelin”) today announces a three-year collaboration with Pfizer Inc. (NYSE: PFE) to design and build what could potentially be an industry-leading platform to evaluate ADME (absorption, distribution, metabolism and excretion) properties of small molecules. The ADME platform will integrate a microphysiological system (MPS), commonly referred to…

Read More

COVISTAT, a Subsidiary of Ensysce Biosciences Inc, a California Based Company With a Mission to Solve the Opioid Crisis, Is Commencing Phase 1 Study of Novel COVID-19 Treatment

10/01/2020

Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–COVISTAT Inc. and its parent company Ensysce, received IND allowance and today initiated a Phase 1 clinical trial of oral nafamostat in healthy volunteers. Nafamostat, an ultra-potent protease inhibitor and an ingredient from Ensysce’s opioid overdose protection platform, is being developed as an oral treatment for COVID-19. The…

Read More

InnovHeart Reports Successful First-in-Human Implantation of its Saturn Transcatheter Mitral Valve with Excellent 30-day Follow-up

09/30/2020

Excerpt from the Press Release: NEWTON, Mass. and MILAN, Sept. 24, 2020 /PRNewswire/ — InnovHeart s.r.l., a developer of novel Transcatheter Mitral Valve Replacement (TMVR) systems for the treatment of Mitral Regurgitation (MR), announced today the successful First-in-Human implantation of its proprietary Saturn Transcatheter Mitral Valve along with excellent results at the 30-day follow-up for the…

Read More

Celebrating Impact of BioScience Sector in PEI During Global Biotech Week

09/28/2020

Excerpt from the Press Release: Charlottetown, PE – From COVID-19 vaccines and diagnostics, to understanding climate change, producing animal health products, and feeding the world sustainably, life sciences continues to be an area of high-demand in solving the challenges facing our society. Dedicated to celebrating science, innovation and solutions, this year’s Global Biotech Week (GBW)…

Read More

Diomics Announces Agreement With Department of Defense to Accelerate Development and Testing of Diocheck™ SARS-CoV-2 Immune Response Indicator Patch

09/25/2020

Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Diomics, a San Diego-based biotech company, today announced that it has been awarded a $2,125,000 Medical Technology Enterprise Consortium (MTEC) Other Transaction Agreement (OTA) with the U.S. Department of Defense to accelerate development and testing of its Diocheck™ SARS-CoV-2 Visual Immune Response Indicator, a transdermal skin patch that…

Read More

Moderna publishes Phase III Covid-19 vaccine study protocol as trial enrolls more than 80% of participants

09/24/2020

Excerpt from the Article: The company said at its R&D day that the Phase III COVE trial of mRNA-1273 had enrolled 25,296 of its planned 30,000 participants, while slightly more than 10,000 had received the first and second doses of the vaccine. One of the most closely watched Phase III Covid-19 vaccine trials is already…

Read More

Ufovax Announces Its Self-Assembling NanoParticles as the Next-Generation Vaccine Solution for COVID-19

09/23/2020

Excerpt from the Press Release: WILMINGTON, Del.–(BUSINESS WIRE)–Ufovax, LLC, (Ufovax), a vaccine biotechnology company based on the patented One-component Self-Assembling protein NanoParticle® (1c-SApNP®) vaccine design and manufacturing platform invented by Associate Professor Jiang Zhu, PhD, of Scripps Research (La Jolla, CA), announced the advancement toward Phase I clinical trials of its next-generation SARS-CoV-2 (aka “COVID-19”)…

Read More

New Coronascape tool will help unlock big-data insights for COVID-19

09/22/2020

Excerpt from the Article: Scientists at Sanford Burnham Prebys Medical Discovery Institute today announced they have released Coronascape (coronascape.org), a customized version of the Metascape bioinformatics platform that removes big-data analysis hurdles for biologists. Coronascape will enable scientists to interpret the growing body of big data related to COVID-19. More than 23,000 papers about COVID-19…

Read More